PTJ
AKBA icon

Paul Tudor Jones’s Akebia Therapeutics AKBA Stock Holding History

Paul Tudor Jones’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-142,274
Closed -$188K – 2968
2024
Q3 		$188K Hold
142,274
– – ﹤0.01% 2548
2024
Q2 		$145K Hold
142,274
– – ﹤0.01% 2186
2024
Q1 		$260K Hold
142,274
– – ﹤0.01% 1920
2023
Q4 		$176K Hold
142,274
– – ﹤0.01% 2216
2023
Q3 		$162K Hold
142,274
– – ﹤0.01% 2114
2023
Q2 		$130K Hold
142,274
– – ﹤0.01% 2278
2023
Q1 		$80K Hold
142,274
– – ﹤0.01% 2271
2022
Q4 		$82K Sell
142,274
-4,434
-3% -$1.39K ﹤0.01% 2231
2022
Q3 		$46K Hold
146,708
– – ﹤0.01% 2191
2022
Q2 		$52K Sell
146,708
-491
-0.3% -$206 ﹤0.01% 1963
2022
Q1 		$106K Buy
147,199
+134,622
+1,070% +$288K ﹤0.01% 1829
2021
Q4 		$28K Buy
+12,577
New +$34.3K ﹤0.01% 2285
2021
Q3 		– Sell
-51,044
Closed -$193K – 2413
2021
Q2 		$193K Sell
51,044
-127,826
-71% -$430K ﹤0.01% 1503
2021
Q1 		$605K Buy
178,870
+3,091
+2% +$11.1K 0.01% 1061
2020
Q4 		$492K Buy
+175,779
New +$513K 0.01% 957
2018
Q2 		– Sell
-21,105
Closed -$201K – 1024
2018
Q1 		$201K Buy
+21,105
New +$295K 0.01% 870
2017
Q3 		– Sell
-12,155
Closed -$175K – 1067
2017
Q2 		$175K Sell
12,155
-5,622
-32% -$71.3K 0.01% 910
2017
Q1 		$164K Sell
17,777
-1,951
-10% -$19K 0.01% 1261
2016
Q4 		$205K Buy
19,728
+1,318
+7% +$11.3K 0.01% 1216
2016
Q3 		$167K Sell
18,410
-388
-2% -$3.3K ﹤0.01% 1288
2016
Q2 		$141K Buy
18,798
+300
+2% +$2.62K ﹤0.01% 1476
2016
Q1 		$167K Buy
+18,498
New +$150K ﹤0.01% 1541

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Paul Tudor Jones's AKBA Position: Q4 2024 in Review

Paul Tudor Jones sold out of Akebia Therapeutics (AKBA) in Q4 2024, closing a stake of 142,274 shares — an estimated $188K sold.

Paul Tudor Jones first reported a position in AKBA in Q1 2016 and held it in 22 quarters. The position peaked at $605K in Q1 2021. 121 funds tracked by Wall St. Rank hold AKBA as of Q4 2024.

  • Paul Tudor Jones reported no remaining Akebia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 142,274 Akebia Therapeutics shares in Q4 2024, an estimated $188K.
  • Paul Tudor Jones first reported a position in Akebia Therapeutics in Q1 2016 and held it in 22 quarters.
  • Paul Tudor Jones's Akebia Therapeutics position peaked at $605K in Q1 2021.
  • 121 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2024.

Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.